Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
100 hedge funds and large institutions have $223M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 34 reducing their positions, and 15 closing their positions.
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding
Funds holding: 100 → 100 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 34
19% less capital invested
Capital invested by funds: $276M → $223M (-$52.9M)
86% less call options, than puts
Call options by funds: $224K | Put options by funds: $1.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.63M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.46M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$1.16M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.03M |
| 5 |
ACM
Altium Capital Management
New York
|
+$954K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.45M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.93M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$1.22M |
| 4 |
Millennium Management
New York
|
-$1.18M |
| 5 |
Morgan Stanley
New York
|
-$849K |
SYRS Hedge Fund Activity: Q3 2021 in Review
100 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2021, worth a combined $223M — down 19% from $276M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SYRS positions and 15 closed out — a net gain of 1 holder — while 29 added to existing stakes and 34 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.63M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.45M sold.
- 100 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $223M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 19% quarter-over-quarter.
- 16 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of +1 holder.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Adage Capital Partners, an estimated $4.63M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was EcoR1 Capital, an estimated $5.45M sold.
Based on aggregated 13F filings for Q3 2021.